多替阿巴拉米片适用于什么病症？

What conditions is it suitable for? Suimeikai is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China; it is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV).

HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Suimeike is the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. It can be taken once a day, one tablet each time, which can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China\Hong Kong, said, "Through effective HIV drug treatment, we can see that the life spans of AIDS patients and healthy people are getting closer and closer. Therefore, drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time, on the Chinese market. The approval of the drug fills this gap and meets the urgent need for convenient medication use by doctors and patients."